Omega Med
This article was originally published in The Gray Sheet
Executive Summary
Initial public offering of 1.2 mil. shares at $5 each is outlined in a prospectus filed with the Securities and Exchange Commission. The San Diego development-stage firm plans to file a 510(k) with FDA in May for its first product, a disposable ambulatory infusion pump. Also in the pipeline is an ear and body-piercing device. Gross proceeds of $6 mil. are tabbed for sales and marketing activities, R&D, and working capital. The firm hopes to raise enough capital to qualify for listing on the Nasdaq small-cap market